Next-gen immunotherapy: a guide for CGT developers
Mar
11
2025
Upcoming webinar

Next-gen immunotherapy: a guide for CGT developers

Tuesday 08:00 PDT / 11:00 EDT / 15:00 GMT / 16:00 CET
Sponsor
Next-gen immunotherapy: a guide for CGT developers

In this webinar, we will uncover the latest techniques in cell and gene therapy to recognize, target, and eliminate cancer cells and tumors. Our experts will examine each major type of cellular immunotherapy, from tumor-infiltrating lymphocytes (TILs) to T-cell receptor (TCR) T cells, CAR-T cells, and natural killer (NK) cells, including autologous and allogeneic options.

We will also review current challenges and opportunities within the CGT workflow for immunotherapy, including:

  • Importance of early analytics
  • Innovations in process development
  • Harnessing genetic modification methods
  • Streamlining the manufacturing process
  • Scaling with fill/finish.

Additionally, we’ll take attendees through a use-case that applies best practices as we move from plasmid starting material through viral vector to gene-modified cell therapy. Last, we’ll cover what you should expect next in the immunotherapy space and how to prepare for it.

  • What you need to know about the most advanced treatments for immunotherapy
  • How to go from process to IND for an autologous CAR-T therapy in weeks
  • How to improve the cell the gene therapy workflows for the top cell therapy treatments, TILs, TCRs, CAR-Ts, and NKs
  • Why qualifying the drug product early accelerates development time and regulatory approvals later in the process
  • Best practices for taking plasmid starting material through viral vector to a gene-modified cell therapy
Alex Sargent
Alex Sargent
Director of Process Development at Charles River Laboratories

Alex Sargent – better known as “Sarge” – is currently the Director of Process Development at Charles River Laboratories. He obtained his PhD from Case Western Reserve University in Cleveland Ohio, where he studied the challenges and promises of stem cell biology, neuroimmunology, and Cleveland sports teams. After a brief stint in academia at the Cleveland Clinic, he left Cleveland to pursue his industry career in cell therapy. During his many years in this industry, he has had the honor of working at several esteemed enterprises on new technologies and approaches for cell therapy scale up, automation, and gene editing. He is especially passionate about the challenge of curing cancer, working on CAR-T and CAR-NK cell therapy process and analytical development from discovery, through regulatory submission, manufacturing, and pivotal clinical trials. He wakes up each day excited to help advance cell and gene therapy to treat and cure disease, with the steadfast goal of improving human lives.

Chad Andersen
Chad Andersen
Associate Director, Manufacturing Sciences and Technology at Charles River Laboratories

Chad is an Associate Director for the Manufacturing Sciences and Technology (MS&T) team which supports the cell therapy CDMO business. He obtained a Biological Sciences degree from the University of Nebraska and began his career in biopharmaceutical manufacturing in 2001. Since, he has held multiple roles in a wide range of biopharma organizations and has experience in early phase through commercial manufacturing operations. Chad is experienced in all aspects of biopharmaceutical production and has a complete understanding of FDA and EU regulations for biologics manufacturing.